NCT00316940View on ClinicalTrials.gov

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

February 28, 2011

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

bortezomib

RADIATION

samarium Sm 153 lexidronam pentasodium

Trial Locations (4)

20817

Center for Cancer and Blood Disorders at Suburban Hospital, Bethesda

90069

West Hollywood

93720

Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno

93309-0633

Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Lead Sponsor

Oncotherapeutics
All Listed Sponsors
lead

Oncotherapeutics

INDUSTRY